#USA #New York #Pomerantz LLP #Biologics License Application #Capricor Therapeutics

Investor Alert: Pomerantz Law Firm Probes Capricor Therapeutics

On June 27, 2025, Pomerantz LLP, a prominent law firm specializing in securities litigation, announced its investigation into claims involving investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm is examining whether Capricor and its executives have engaged in any unlawful business practices or securities fraud. Investors who believe they may have been affected are encouraged to contact Pomerantz for guidance.

Background of Capricor Therapeutics

Capricor is a clinical-stage biotechnology company focused on the research and development of novel therapies for some of the most challenging medical conditions. One of its primary investigative products is deramiocel, a cell therapy aimed at treating patients suffering from Duchenne muscular dystrophy (DMD) cardiomyopathy. This drug is currently undergoing the regulatory review process by the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA).

Recent Developments and Stock Price Reactions

The firm’s investigation comes in the wake of detrimental news affecting Capricor's stock price. On May 5, 2025, Capricor announced that the FDA had confirmed its intent to hold an advisory committee meeting to discuss the BLA for deramiocel. This development initially led to a positive reaction from the market; however, the stock took a sharp downturn the following day, plummeting $3.00 per share (29.13%) to close at $7.30 after the announcement.

Further exacerbating the situation, a report by STAT on June 20, 2025, indicated that the new head of the relevant FDA division had canceled the much-anticipated advisory meeting amid growing concerns about the drug’s efficacy and safety. Following this revelation, Capricor's share price experienced another significant decline, falling another $3.68 per share (30.82%) to close at $8.26.

These dramatic fluctuations in stock value raise critical questions regarding the company’s communications and the implications of its drug approval process. Investors are left pondering whether they were misled about the viability of deramiocel or if adequate disclosures were provided regarding the risks associated with the therapy.

Role of Pomerantz LLP

Pomerantz LLP has established itself as a leader in corporate, securities, and antitrust class action litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm has a long history of fighting for victims of corporate misconduct and securities fraud. Passionate about their mission, Pomerantz has secured substantial settlements for investors and aims to ensure that those who may have been harmed by Capricor's business practices receive the justice they deserve.

As outlined in the firm's announcement, investors who wish to join this investigation or seek assistance regarding their potential claims are encouraged to reach out to Danielle Peyton through the provided contact details.

Conclusion

The investigation by Pomerantz Law Firm into Capricor Therapeutics highlights the ongoing concerns surrounding corporate governance and transparency in the biotechnology sector. For investors, staying informed and understanding their rights in such situations is crucial as they navigate potential losses associated with their investments. As this story develops, stakeholders in the industry will undoubtedly watch closely, hoping for a resolution that upholds accountability and investor protection.